H. Lee Moffitt Cancer Center and Research Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, H. Lee Moffitt Cancer Center and Research Institute sits in the top decile of US sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count).
H. Lee Moffitt Cancer Center and Research Institute: 502 sponsored US clinical trials, 82 recruiting.
H. Lee Moffitt Cancer Center and Research Institute sponsors 502 registered US clinical trials on ClinicalTrials.gov, 82 of them currently recruiting, and 280 completed. 5 of these trials are in Phase 3-4 (later-stage) and 335 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
H. Lee Moffitt Cancer Center and Research Institute ranks in the top decile of sponsors by registered trial count (#72 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
280 of 344 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
502 total, page 9 of 11
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
NCT00762255
Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
NCT00747643
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
NCT00750815
Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
NCT00803010
Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection
NCT00751140
Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients
NCT00815750
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
NCT00720096
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
NCT00665002
Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)
NCT00673738
Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant
NCT00660400
Pilot Study to Validate Metallic Markers for Image Guided Radiation Therapy for Breast Cancer Tx
NCT00802932
Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts
NCT00624585
Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)
NCT00617591
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
NCT00720629
Study of Polyphenon E in Men With High-grade Prostatic Intraepithelial Neoplasia
NCT00596011
A Phase I/II Study of Dasatinib and Dacarbazine
NCT00597038
To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
NCT00617409
Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab
NCT00609869
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
NCT00604461
Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer
NCT01662609
Effects of Yoga and Cardiovascular Exercise on Smoking Motivation
NCT01423578
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
NCT00609765
A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia
NCT00815685
Phase II Trial of Pentostatin and Targeted Busulfan
NCT00496340
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
NCT00612677
Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC
NCT00499109
Patient Navigator Project
NCT00375024
Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma
NCT00598507
Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer
NCT00776295
A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
NCT00480584
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
NCT00606008
Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT00444015
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma
NCT00504257
Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases
NCT00437957
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
NCT00434109
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
NCT00400569
The Human Papillomavirus (HPV) Transmission Pilot Study
NCT00823511
Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer
NCT00601796
Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
NCT00495625
A Phase I/II Study of Sunitinib and Dacarbazine
NCT00496223
Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy
NCT00387647
Support for People Undergoing Chemotherapy
NCT00740038
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
NCT00351039
Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma
NCT00365222
Drug /Cue Interactions In Alcohol-Tobacco Comorbidity
NCT00816231
External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma
NCT00365872
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
NCT00363467
Evaluation of Patient Functionality and Utility of Web-Based Personal Health History and Risk Assess
NCT00822822
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
NCT00365599
Dendritic Cell Vaccination During Lymphoid Reconstruction
NCT00313508
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 167 |
| Phase 2 | 168 |
| Phase 3 | 3 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the H. Lee Moffitt Cancer Center and Research Institute pipeline
82 recruiting of 502 indexed (16% open); 280 completed (56%).
Phase mix: 5 late (III/IV) vs 335 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
H. Lee Moffitt Cancer Center and Research Institute: open-pipeline peers nationwide
Peers matched on 502 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
H. Lee Moffitt Cancer Center and Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 502 trials (± recruiting share)
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- Gilead Sciences · 504 trials · 5% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Boehringer Ingelheim · 515 trials · 8% recruiting
Sponsors near 16% open enrollment (± trial volume)
- Case Western Reserve University · 16% recruiting · 141 trials
- Drexel University · 16% recruiting · 92 trials
- Atlantic Health System · 16% recruiting · 43 trials
- BioMarin Pharmaceutical · 16% recruiting · 80 trials
Related
What to do with this H. Lee Moffitt Cancer Center and Research Institute page
502 registered trials is a research-attention snapshot, not an endorsement of H. Lee Moffitt Cancer Center and Research Institute or any single study.
- 82 of H. Lee Moffitt Cancer Center and Research Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition H. Lee Moffitt Cancer Center and Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. H. Lee Moffitt Cancer Center and Research Institute pipeline card: 502 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.